Screener
Xeris Biopharma Holdings, Inc. XERS Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Product revenue, net by Product | ||||||
| Gvoke | $22.55M-3.9% | $20.8M-0.2% | $24.65M+5.9% | $25.15M+9.6% | $23.47M+17.1% | |
| Keveyis | $11.68M+1.7% | $11.89M+4.0% | $12.8M+15.1% | $11.94M-2.1% | $11.49M-12.5% | |
| Other product revenue | $0-100% | —— | $651K— | $0— | $1.31M— | |
| Recorlev | $56.78M+80.6% | $49.77M+94.9% | $45.33M+100% | $36.98M+109% | $31.44M+136% | |
| Royalty, contract and other revenue | $1.1M-71.4% | $673K-71.0% | $2.38M-23.3% | $317K-77.5% | $3.83M+147% |
FAQ
- How does Xeris Biopharma Holdings, Inc. break its business down?
- Xeris Biopharma Holdings, Inc. (XERS) reports product revenue, net by product across 5 parts — Gvoke, Keveyis, Other product revenue, Recorlev and Royalty, contract and other revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Xeris Biopharma Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Xeris Biopharma Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
